TAXUS ATLAS LONG LESION: A multi-center, single-arm study of the TAXUS Liberte-SR stent for the treatment of patients with long de novo coronary artery lesions.

Trial Profile

TAXUS ATLAS LONG LESION: A multi-center, single-arm study of the TAXUS Liberte-SR stent for the treatment of patients with long de novo coronary artery lesions.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Angina pectoris; Coronary artery disease; Coronary artery restenosis; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms ATLAS-Long-Lesion
  • Sponsors Boston Scientific Corporation
  • Most Recent Events

    • 22 Sep 2009 Three-year results were presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, according to a Boston Scientific media release.
    • 05 Feb 2009 Clinical data from this trial form part of the pre-marketing approval application submitted to the FDA for Taxus Liberte Long paclitaxel-eluting coronary stent system, according to a media release from Boston Scientific.
    • 01 Dec 2008 Primary endpoint 'In stent restenosis' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top